Pharma News, PharmaTutor, pharma recruitment agencies.#Pharma #recruitment #agencies


Posted On Feb 14 2018 by

Pharma News

  • Posted on: 13 November 2017
  • By: admin

In last month, there was lot of hike about osemertinib is being sold illegally in the Hyderabad by private and government hospitals despite a ban by the Drug Controller General of India (DCGI). But on last Friday, DCGI confirmed that only AstraZeneca Pharma India Limited, Bangalore has given permission for import and marketing of cancer drug.

  • Read more about Astrazeneca s osemertinib is only approved in India
  • Log in or register to post comments

USFDA Expands Approval of Sprycel® (dasatinib) for children with Philadelphia chromosome

  • Posted on: 11 November 2017
  • By: PharmaTutor News

Bristol-Myers Squibb Company announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel ® (dasatinib) tablets to include the treatment of children with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP).

  • Read more about USFDA Expands Approval of Sprycel® (dasatinib) for children with Philadelphia chromosome
  • Log in or register to post comments

Adoptive cell therapy shows durable anti-tumor response

  • Posted on: 10 November 2017
  • By: PharmaTutor News

In recent years, the search for new cancer treatments has increasingly focused on immunotherapies that harness the body’s own defenses to fight tumors. Adoptive cell therapy (ACT) is a powerful immunotherapeutic strategy that can effectively control some cancers but that also has drawbacks. To administer ACT, T cells are withdrawn from a patient and cultivated in a laboratory (ex vivo) for weeks or months, until a massive number of cells are available to be injected back into the patient. During ex vivo cultivation, the T cells often lose potency and life span.

  • Read more about Adoptive cell therapy shows durable anti-tumor response
  • Log in or register to post comments

Nitric oxide: Experimental analysis of its role in brain tissue in simulated ischemia

  • Posted on: 10 November 2017
  • By: PharmaTutor News

A joint study conducted by scientists at the National Academy of Sciences in Belarus and Kazan Federal University in Russia, looks at the role of nitric oxide (NO) in brain tissue in simulated ischemia in rats.

  • Read more about Nitric oxide: Experimental analysis of its role in brain tissue in simulated ischemia
  • Log in or register to post comments

Celgene Corporation s Ozanimod shows positive effect in Multiple Sclerosis

  • Posted on: 10 November 2017
  • By: PharmaTutor News

Celgene Corporation recently announced results from two phase 3 trials evaluating the efficacy and safety of the drug ozanimod. Ozanimod was invented by scientists at The Scripps Research Institute (TSRI). Ozanimod is a novel, oral, selective sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator, and was compared to the first-line treatment, Avonex® (interferon beta-1a) (IFN), in patients with relapsing multiple sclerosis (RMS). The findings from the two pivotal phase 3 (SUNBEAM and RADIANCE Part B) trials pave the way for ozanimod to enter the New Drug Approval process with the U.S. Food and Drug Administration (FDA).

  • Read more about Celgene Corporation s Ozanimod shows positive effect in Multiple Sclerosis
  • Log in or register to post comments

HPV Vaccine Prevents Uncommon Childhood Respiratory Disease

  • Posted on: 10 November 2017
  • By: PharmaTutor News

The vaccine that protects against cancer-causing types of human papillomavirus (HPV) also prevents an uncommon but incurable childhood respiratory disease, according to a new study published in The Journal of Infectious Diseases. The findings suggest that the chronic and difficult-to-treat condition, recurrent respiratory papillomatosis, is disappearing in Australian children as a result of the nation’s highly successful HPV vaccination program.

  • Read more about HPV Vaccine Prevents Uncommon Childhood Respiratory Disease
  • Log in or register to post comments

Alembic Completes Acquisition of US based Generic Drug Developer Orit Laboratories

  • Posted on: 8 November 2017
  • By: PharmaTutor News

Alembic Pharmaceuticals Ltd announced that through its 100% owned subsidiary, Alembic Pharmaceuticals Inc., it has completed acquisition of West Caldwell, New Jersey, U.S.A. based generic drug developer Orit Laboratories LLC (“Orit”) along with real estate, owned by Okner Realty LLC (“Okner”).

  • Read more about Alembic Completes Acquisition of US based Generic Drug Developer Orit Laboratories
  • Log in or register to post comments

Dr. Reddy s Laboratories announces the launch of generic Azacitidine for Injection in the Canadian Market

  • Posted on: 8 November 2017
  • By: PharmaTutor News

Dr. Reddy’s Laboratories Ltd. is pleased to announce that generic Azacitidine for injection 100 mg/vial, a bioequivalent generic version of VIDAZA® (azacitidine for injection), is approved by Health Canada

  • Read more about Dr. Reddy s Laboratories announces the launch of generic Azacitidine for Injection in the Canadian Market
  • Log in or register to post comments

Biosimilar of Humira maintained same efficacy

  • Posted on: 8 November 2017
  • By: PharmaTutor News

Boehringer Ingelheim announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira®*. The 48-week data showed that Cyltezo® is equivalent, with no clinically meaningful differences in efficacy, safety and immunogenicity to Humira® in people with moderately-to-severely active rheumatoid arthritis (RA), including in patients who switched from Humira® to Cyltezo® at week 24.

  • Read more about Biosimilar of Humira maintained same efficacy
  • Log in or register to post comments

New dengue vaccine associated with reduction in the incidence of dengue in children and adolescents

  • Posted on: 8 November 2017
  • By: PharmaTutor News

Takeda Pharmaceutical Company Limitedannounced that data from an 18-month interim analysis of the ongoing Phase 2 DEN-204 trial of its live, attenuated tetravalent dengue vaccine candidate, TAK-003 (also referred to as TDV), have been published in The Lancet Infectious Diseases. The results of this interim analysis, a pre-planned evaluation of data from an ongoing trial, show that TAK-003 is associated with a reduction in the incidence of dengue in children and adolescents. These data were also presented at the American Society of Tropical Medicine and Hygiene Annual Meeting. Phase 3 data are required to confirm these findings.


Last Updated on: February 14th, 2018 at 5:47 am, by


Written by admin


Leave a Reply

Your email address will not be published. Required fields are marked *